{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:58:54Z","timestamp":1790078334022,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Gastrointestinal nematodes are parasites that commonly infect dogs, and infections can be subclinical or may cause considerable clinical disease. Some species are zoonotic and may also cause clinical disease in humans. Year-round treatment of dogs is recommended to eliminate existing infections, which also indirectly reduces the potential for subsequent human exposure to zoonotic species. Here we present two studies that evaluated the safety and efficacy of a novel chewable oral tablet containing sarolaner, moxidectin and pyrantel against gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Dogs naturally infected with <jats:italic>Toxocara canis<\/jats:italic>, <jats:italic>Toxascaris leonina<\/jats:italic>, <jats:italic>Ancylostoma caninum<\/jats:italic> and\/or <jats:italic>Uncinaria stenocephala<\/jats:italic> were enrolled in the European study, and dogs naturally infected with <jats:italic>T. canis<\/jats:italic> were enrolled in the USA study. The animals were treated once orally with Simparica Trio\u2122 tablets to provide 1.2\u20132.4 mg\/kg sarolaner, 24\u201348 \u00b5g\/kg moxidectin and 5\u201310 mg\/kg pyrantel (as pamoate salt) or with a commercially available product according to the label directions as positive control. Efficacy was based on the post-treatment reduction in geometric mean egg counts (per gram feces) 7 or 10 days after treatment compared to pre-treatment egg counts.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Simparica Trio\u2122 was well tolerated in both studies. In the European study, geometric mean egg counts for <jats:italic>T. canis<\/jats:italic>, <jats:italic>T. leonina<\/jats:italic>, <jats:italic>A. caninum<\/jats:italic> and <jats:italic>U. stenocephala<\/jats:italic> were reduced by\u2009\u2265\u200998.3% in the Simparica Trio\u2122 group and by\u2009\u2265\u200997.4% in the afoxolaner\u2009+\u2009milbemycin oxime group. In the USA study, geometric mean egg counts for <jats:italic>T. canis<\/jats:italic> were reduced by 99.2% in the Simparica Trio\u2122 group and by 98.6% in the ivermectin\u2009+\u2009pyrantel group. In the USA study, 48 and 10 dogs in the Simparica Trio\u2122 and the ivermectin\u2009+\u2009pyrantel group, respectively, were co-infected with <jats:italic>A. caninum<\/jats:italic> and the reduction in the post-treatment mean fecal egg counts were 98.6% and 74.7%, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A single oral administration of Simparica Trio\u2122 chewable tablets was well tolerated and was effective in the treatment of dogs with naturally occurring gastrointestinal nematode infections presented as veterinary patients in Europe and the USA.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13071-020-3947-0","type":"journal-article","created":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:03:04Z","timestamp":1583020984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio\u2122) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA"],"prefix":"10.1186","volume":"13","author":[{"given":"Csilla","family":"Becskei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kryda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Fias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Follis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Wozniakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Mahabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,1]]},"reference":[{"key":"3947_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.vetpar.2012.12.035","volume":"193","author":"PA Overgaauw","year":"2013","unstructured":"Overgaauw PA, Van Knapen F. Veterinary and public health aspects of Toxocara spp. Vet. Parasitol. 2013;193:398\u2013403.","journal-title":"Vet. Parasitol."},{"key":"3947_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pt.2010.01.005","volume":"26","author":"DD Bowman","year":"2010","unstructured":"Bowman DD, Montgomery SP, Zajac AM, Eberhard ML, Kazacos KR. Hookworms of dogs and cats as agents of cutaneous larva migrans. Trends Parasitol. 2010;26:162\u20137.","journal-title":"Trends Parasitol."},{"key":"3947_CR3","unstructured":"Companion Animal Parasite Council. CAPC guideline on ascarids for dogs; 2016. https:\/\/capcvet.org\/guidelines\/ascarid\/. Accessed 12 Mar 2019."},{"key":"3947_CR4","unstructured":"Companion Animal Parasite Council. CAPC guideline on hookworms for dogs; 2016. https:\/\/capcvet.org\/guidelines\/hookworms\/. Accessed 12 Mar 2019."},{"key":"3947_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-3950-5","author":"C Becskei","year":"2020","unstructured":"Becskei C, Kryda K, Thys M, Holzmer S, Bowersock L, Fernandez T, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio\u2122) against induced ascarid infections in dogs. Parasit Vectors. 2020. https:\/\/doi.org\/10.1186\/s13071-020-3950-5.","journal-title":"Parasit Vectors."},{"key":"3947_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-3951-4","author":"C Becskei","year":"2020","unstructured":"Becskei C, Thys M, Kryda K, Meyer L, Martorell S, Geurden T, et al. Efficacy of Simparica Trio\u2122, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs. Parasit Vectors. 2020. https:\/\/doi.org\/10.1186\/s13071-020-3951-4.","journal-title":"Parasit Vectors."},{"key":"3947_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0304-4017(94)90110-4","volume":"52","author":"DE Jacobs","year":"1994","unstructured":"Jacobs DE, Arakawa A, Courtney CH, Gemmell MA, McCall JW, Myers GH, et al. World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) guidelines for evaluating the efficacy of anthelmintics for dogs and cats. Vet. Parasitol. 1994;52:179\u2013202.","journal-title":"Vet. Parasitol."},{"key":"3947_CR8","unstructured":"EMEA. Guideline on good clinical practices. VICH Topic GL9. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/vich-gl9-good-clinical-practices-step-7_en.pdf. Accessed 12 Mar 2019."},{"key":"3947_CR9","first-page":"40","volume-title":"Veterinary clinical parasitology","author":"AM Zajac","year":"2012","unstructured":"Zajac AM, Conboy GA. Veterinary clinical parasitology. Hoboken: Wiley-Blackwell; 2012. p. 40\u201387."},{"key":"3947_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00436-016-5287-8","volume":"116","author":"S Rehbein","year":"2017","unstructured":"Rehbein S, Knaus M, Mallouk Y, Breiltgens T, Brianti E, Cap\u00e1ri B, et al. Efficacy against nematode infections and safety of afoxolaner plus milbemycin oxime chewable tablets in domestic dogs under field conditions in Europe. Parasitol Res. 2017;116:259\u201369.","journal-title":"Parasitol Res."},{"key":"3947_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0020-7519(85)90041-4","volume":"15","author":"TM Burke","year":"1985","unstructured":"Burke TM, Roberson EL. Prenatal and lactational transmission of Toxocara cams and Ancylostoma caninum: Experimental infection of the bitch at mid pregnancy and at parturition. Int J Parasitol. 1985;15:485\u201390.","journal-title":"Int J Parasitol."},{"key":"3947_CR12","unstructured":"European Scientific Counsel Companion Animal Parasites. ESCCAP Guidelines: https:\/\/www.esccap.org\/guidelines\/. Accessed 12 Mar 2019."},{"key":"3947_CR13","unstructured":"Companion Animal Parasite Council. CAPC Guidelines: https:\/\/capcvet.org\/guidelines\/. Accessed 12 Mar 2019."},{"key":"3947_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s13071-019-3702-6","volume":"12","author":"K Kryda","year":"2019","unstructured":"Kryda K, Six RH, Walsh KF, Holzmer SJ, Chapin S, Mahabir SP, et al. Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing sarolaner, moxidectin and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2019;12:445.","journal-title":"Parasit Vectors."},{"key":"3947_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-3952-3","author":"K Kryda","year":"2020","unstructured":"Kryda K, Mahabir SP, Inskeep T, Rugg J. Efficacy and safety of a novel oral chewable combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio\u2122) against fleas on dogs presented as veterinary patients in the USA. Parasit Vectors. 2020. https:\/\/doi.org\/10.1186\/s13071-020-3952-3.","journal-title":"Parasit Vectors."},{"key":"3947_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-3946-1","author":"C Becskei","year":"2020","unstructured":"Becskei C, Fias D, Mahabir SP, Farkas R. Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio\u2122) against natural flea and tick infestations on dogs presented as veterinary patients in Europe. Parasit Vectors. 2020. https:\/\/doi.org\/10.1186\/s13071-020-3946-1.","journal-title":"Parasit Vectors."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-3947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-020-3947-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-3947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:05:12Z","timestamp":1614557112000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-3947-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3947"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-3947-0","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,1]]},"assertion":[{"value":"17 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocols were reviewed and approved by the Zoetis Ethical Review Board and by the Zoetis Ethics Review Assessment team prior to implementation. Informed owner consent was obtained prior to the enrollment of all dogs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was funded by Zoetis, Parsippany, NJ, USA. CB, KK, DF, SF, MW and SPM were employees of Zoetis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}